Company Scilex Holding Company

SCLX

US80880W2052

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2026-05-11 EDT			5-day change	1st Jan Change
6.900 ^USD	-11.76%		-38.12%	-43.44%

05-05	Scilex Unit to Transfer ACEA Pharma to Phoenix Asia in $1 Billion All-Stock Deal	MT
05-05	O+C Private Credit Wade defendants dispute complaint and statement by Scilex Holding company	RE

Business description: Scilex Holding Company

Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Companyâ€™s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.

Number of employees: 34

Sales by Activity: Scilex Holding Company

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Development of Non-Opioid Products	31.32M	38.03M	46.74M	56.59M	30.25M

See all business segments

Geographical breakdown of sales: Scilex Holding Company

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
United States	31.32M	38.03M	46.74M	56.59M	30.25M

See all geographic segments

Executive Committee: Scilex Holding Company

Manager	Title	Age	Since
Henry Ji CEO	Chief Executive Officer	61	2025-08-16
Stephen Ma DFI	Director of Finance/CFO	53	2023-09-21
Elaine Chan CTO	Chief Tech/Sci/R&D Officer	-	2021-12-31
Steve Lincoln CMP	Compliance Officer	-	-
Dmitri V. Lissin CTO	Chief Tech/Sci/R&D Officer	57	-

See SCILEX HOLDING COMPANY governance

Composition of the Board of Directors: Scilex Holding Company

Director	Title	Age	Since
Dorman Followwill BRD	Director/Board Member	62	2022-11-09
Stephen Ma BRD	Director/Board Member	53	2025-09-21
Jay Chun BRD	Director/Board Member	62	2023-09-21
Yue Wu BRD	Director/Board Member	62	2023-09-21
Henry Ji CHM	Chairman	61	2023-09-21

Composition of the Board of Directors

Shareholders: Scilex Holding Company

Name	Equities	%	Valuation
SCLX Stock Acquisition JV LLC 17.17 %	1,458,263	17.17 %	10 M $
Armistice Capital LLC 5.614 %	476,674	5.614 %	3 M $
Vanguard Capital Management LLC (Pennsylvania) 3.11 %	264,050	3.11 %	2 M $
BlackRock Institutional Trust Co. NA 1.146 %	97,289	1.146 %	647 945 $
Vanguard Fiduciary Trust Co. 0.5016 %	42,595	0.5016 %	283 683 $

Name	Equities	%	Valuation
SCLX Stock Acquisition JV LLC 100 %	29,057,097	100 %	194 M $

Name	Equities	%	Valuation
Cruiser Capital Advisors LLC 0.3795 %	49,999	0.3795 %	5 500 $
Virtu Financial LLC 0.3615 %	47,634	0.3615 %	5 240 $
Landscape Capital Management LLC 0.3326 %	43,824	0.3326 %	4 821 $
Clear Street Group, Inc. 0.0219 %	2,880	0.0219 %	317 $

List of SCILEX HOLDING COMPANY shareholders

Holdings: Scilex Holding Company

Name	Equities	%	Valuation
Semnur Pharmaceuticals, Inc. 81.91%	188,554,849	81.91%	1 414 M $
DATAVAULT AI INC. 30.6%	213,766,229	30.6%	155 M $

Company details: Scilex Holding Company

Scilex Holding Co.

960 San Antonio Road

94303, Palo Alto

http://www.scilexholding.com

Specialty & Advanced Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SCILEX HOLDING COMPANY	-11.76%	-38.12%	+72.07%	-96.31%	55M
MERCK KGAA	+0.04%	+3.20%	-8.47%	-31.68%	57.75B
KYOWA KIRIN CO., LTD.	-0.99%	-1.32%	+10.37%	-10.46%	7.77B
HALOZYME THERAPEUTICS, INC.	+3.57%	+2.85%	+0.82%	+101.30%	7.6B
SK BIOPHARMACEUTICALS CO., LTD.	-0.80%	-1.30%	+9.07%	+39.86%	5.33B
YUHAN CORPORATION	-2.31%	-7.64%	-21.08%	+54.49%	4.4B
BETTA PHARMACEUTICALS CO., LTD.	+3.67%	+2.68%	+5.23%	-20.36%	3.18B
SUPERNUS PHARMACEUTICALS, INC.	-4.19%	+1.52%	+55.74%	+37.52%	2.99B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-0.51%	+0.65%	+21.35%	+18.36%	2.55B
SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.	+0.32%	+0.26%	+82.56%	+35.23%	2.04B
Average	-1.29%	-2.50%	+22.77%	+12.80%	9.37B
Weighted average by Cap.	+0.06%	+1.77%	-0.39%	-5.64%